Conor A. Bradley

Conor A. Bradley

Auto-generated profile, based on publicly available information

Conor A. Bradley

Nature Reviews Cancer, .

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2017 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
OCon behalf of the MErCuRIC consortium
on behalf of the MErCuRIC consortium
CBConor A. Bradley
Conor A. Bradley
MSManuel Salto-Tellez
Manuel Salto-Tellez
PLPierre Laurent-Puig
Pierre Laurent-Puig
ABAlberto Bardelli
Alberto Bardelli
SSSandra Van Schaeybroeck
Sandra Van Schaeybroeck

14 August 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PDPhilip Dunne
Philip Dunne
DMDarragh McArt
Darragh McArt
CBConor A. Bradley
Conor A. Bradley
POPaul G. O'REilly
Paul G. O'REilly
HBHelen L. Barrett
Helen L. Barrett
SSSandra Van Schaeybroeck
Sandra Van Schaeybroeck
Purpose: A number of independent gene expression profiling studies have identified transcriptional subtypes in colorectal cancer with potential diagnostic utility, culminating in publication of a colorectal cancer Consensus Molecular Subtype classification. The worst prognostic subtype has been defined by genes associated with stem-like biology. Recently, it has been shown that the majority of genes associated with this poor prognostic group are stromal derived. We investigated the potential for tumor misclassification into multiple diagnostic subgroups based on tumoral region sampled. Experimental Design: We performed multiregion tissue RNA extraction/transcriptomic analysis using colorectal-specific arrays on invasive front, central tumor, and lymph node regions selected from tissue samples from 25 colorectal cancer patients. Results: We identified a consensus 30-gene list, which represents the intratumoral heterogeneity within a cohort of primary colorectal cancer tumors. Using a series of online datasets, we showed that this gene list displays prognostic potential HR = 2.914 (confidence interval 0.9286–9.162) in stage II/III colorectal cancer patients, but in addition, we demonstrated that these genes are stromal derived, challenging the assumption that poor prognosis tumors with stem-like biology have undergone a widespread epithelial–mesenchymal transition. Most importantly, we showed that patients can be simultaneously classified into multiple diagnostically relevant subgroups based purely on the tumoral region analyzed. Conclusions: Gene expression profiles derived from the nonmalignant stromal region can influence assignment of colorectal cancer transcriptional subtypes, questioning the current molecular classification dogma and highlighting the need to consider pathology sampling region and degree of stromal infiltration when employing transcription-based classifiers to underpin clinical decision making in colorectal cancer. Clin Cancer Res; 22(16); 4095–104. ©2016 AACR. See related commentary by Morris and Kopetz, p. 3989

1 January 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PDPhilip Dunne
Philip Dunne
SDSonali Dasgupta
Sonali Dasgupta
JBJaine K. Blayney
Jaine K. Blayney
DMDarragh McArt
Darragh McArt
KRKeara L. Redmond
Keara L. Redmond
SSSandra Van Schaeybröeck
Sandra Van Schaeybröeck
Purpose: EphA2, a member of the Eph receptor tyrosine kinases family, is an important regulator of tumor initiation, neovascularization, and metastasis in a wide range of epithelial and mesenchymal cancers; however, its role in colorectal cancer recurrence and progression is unclear. Experimental Design: EphA2 expression was determined by immunohistochemistry in stage II/III colorectal tumors (N = 338), and findings correlated with clinical outcome. The correlation between EphA2 expression and stem cell markers CD44 and Lgr5 was examined. The role of EphA2 in migration/invasion was assessed using a panel of KRAS wild-type (WT) and mutant (MT) parental and invasive colorectal cancer cell line models. Results: Colorectal tumors displayed significantly higher expression levels of EphA2 compared with matched normal tissue, which positively correlated with high CD44 and Lgr5 expression levels. Moreover, high EphA2 mRNA and protein expression were found to be associated with poor overall survival in stage II/III colorectal cancer tissues, in both univariate and multivariate analyses. Preclinically, we found that EphA2 was highly expressed in KRASMT colorectal cancer cells and that EphA2 levels are regulated by the KRAS-driven MAPK and RalGDS-RalA pathways. Moreover, EphA2 levels were elevated in several invasive daughter cell lines, and downregulation of EphA2 using RNAi or recombinant EFNA1 suppressed migration and invasion of KRASMT colorectal cancer cells. Conclusions: These data show that EpHA2 is a poor prognostic marker in stage II/III colorectal cancer, which may be due to its ability to promote cell migration and invasion, providing support for the further investigation of EphA2 as a novel prognostic biomarker and therapeutic target. Clin Cancer Res; 22(1); 230–42. ©2015 AACR.

26 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CBConor A. Bradley
Conor A. Bradley
PDPhilip Dunne
Philip Dunne
VBVictoria Bingham
Victoria Bingham
SMStephen McQuaid
Stephen McQuaid
HKHajrah Khawaja
Hajrah Khawaja
SSSandra Van Schaeybröeck
Sandra Van Schaeybröeck
Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer

1 October 2016 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
KMKylie A. McLaughlin
Kylie A. McLaughlin
ZNZsuzsanna Németh
Zsuzsanna Németh
CBConor A. Bradley
Conor A. Bradley
LHLuke Humphreys
Luke Humphreys
ISIzabela Stasik
Izabela Stasik
Daniel LongleyDaniel Longley
Daniel Longley
Resistance to radiotherapy due to insufficient cancer cell death is a significant cause of treatment failure in non–small cell lung cancer (NSCLC). The endogenous caspase-8 inhibitor FLIP is a critical regulator of cell death that is frequently overexpressed in NSCLC and is an established inhibitor of apoptotic cell death induced via the extrinsic death receptor pathway. Apoptosis induced by ionizing radiation (IR) has been considered to be mediated predominantly via the intrinsic apoptotic pathway; however, we found that IR-induced apoptosis was significantly attenuated in NSCLC cells when caspase-8 was depleted using RNA interference (RNAi), suggesting involvement of the extrinsic apoptosis pathway. Moreover, overexpression of wild-type FLIP, but not a mutant form that cannot bind the critical death receptor adaptor protein FADD, also attenuated IR-induced apoptosis, confirming the importance of the extrinsic apoptotic pathway as a determinant of response to IR in NSCLC. Importantly, when FLIP protein levels were downregulated by RNAi, IR-induced cell death was significantly enhanced. The clinically relevant histone deacetylase (HDAC) inhibitors vorinostat and entinostat were subsequently found to sensitize a subset of NSCLC cell lines to IR in a manner that was dependent on their ability to suppress FLIP expression and promote activation of caspase-8. Entinostat also enhanced the antitumor activity of IR in vivo. Therefore, FLIP downregulation induced by HDAC inhibitors is a potential clinical strategy to radiosensitize NSCLC and thereby improve response to radiotherapy. Overall, this study provides the first evidence that pharmacological inhibition of FLIP may improve response of NCSLC to IR. Mol Cancer Ther; 15(10); 2432–41. ©2016 AACR.

4 September 2012 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
WAWilliam J. Andrews
William J. Andrews
CBConor A. Bradley
Conor A. Bradley
EHElaine Hamilton
Elaine Hamilton
CDClare Daly
Clare Daly
TMThérèse Mallon
Thérèse Mallon
David J. TimsonDavid J. Timson
David J. Timson